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Human TAFII105 Is a Cell Type–Specific
TFIID Subunit Related to hTAFII130
Rivka Dikstein, Sharleen Zhou, and Robert Tjian et al., 1995; Sauer et al., 1995). More importantly, tran-
scription reactions reconstitutedwith recombinant TAFsHoward Hughes Medical Institute
are able to provide coactivator function and thus po-Department of Molecular and Cell Biology
tentiate enhancer-dependent activation by sequence-University of California
specific regulators (Chen et al., 1994; Thut et al., 1995;Berkeley, California 94720-3204
Sauer et al., 1995). In addition, the assembly of partial
TBP–TAF complexes has suggested that specific activa-
tor–TAF interactions are required to direct both simpleSummary
activation as well as synergistic transcription by multiple
enhancer factors (Sauer et al., 1995). Finally, there isWe previously characterized Drosophila and human
emerging evidence that at least in metazoans, TAFs areTAF subunits that make up the core TFIID complex
also important for mediating activation of transcriptionfound in all cells. Here, we report that differentiated
in vivo (Sekiguchi et al., 1991; Ruppert et al., 1993; WangB cells contain a novel substoichiometric TAF of 105
and Tjian, 1994). Thus, there is a growing body of evi-kDa not found associated with TFIID isolated from
dence that implicates TFIID as a major integrator ofother cell types. The cDNA encoding hTAFII105 reveals
transcriptional activation signals.a highly conserved C-terminal domain shared by
The initial models for coactivator-mediated transcrip-hTAFII130 and dTAFII110, while the N-terminal coacti-
tion envisioned that multiple surfaces presented by thevator domain has diverged significantly. All cells tested
TBP–TAF complex could provide the necessary con-express TAFII105 mRNA, but only B cells contain signif-
tacts to accommodate large numbers of different activa-icant levels of protein associated with TFIID. Transient
tors (Pugh and Tjian, 1990; Dynlacht et al., 1991; Zhouoverexpression of hTAFII105 selectively squelches the
et al., 1992; Chen et al., 1994). Also, there was evidencetranscription of some genes in B cells. These proper-
that different activators of a given class (i.e., glutamine-ties suggest that TAFII105 is a cell type–specific sub- rich, acidic, etc.) target common TAFs within TFIID (Hoeyunit of TFIID that may be responsible for mediating
et al., 1993; Goodrich et al., 1993; Chen et al., 1994;transcription by a subset of activators in B cells.
Thut et al., 1995; Sauer et al., 1995). Recently, there has
been both structural and genetic evidence to suggest
Introduction that rather small patches of protein surfaces may be
sufficient to provide specific points of contact between
The regulation of gene expression during development, components in the preinitiation complex (Nikolov et al.,
differentiation, and cell growth of metazoans is thought 1995; Tang et al., 1996). It therefore seemed reasonable
to be directed by a large number of different sequence- to hypothesize that the 8–10 TAFs in the TFIID complex
specific DNA-binding transcription factors. This enor- might be enough to integrate most of the activator sig-
mous diversity of enhancer- and promoter-specific acti- nals in the eukaryotic cell.
vators in turn must somehow control the activity of RNA However, it seemed possible that in metazoans with
polymerase II and its associated transcriptional machin- highly elaborated tissue-specific and developmentally
ery. Extensive biochemical and genetic analysis carried regulated programs of transcription, there might be a
out over the past decade reveals an elaborate cascade need for tissue-specific constituents of the transcription
of protein–DNA and protein–protein transactions that machinery, including TAFs. The finding that yeast con-
collectively govern the levels of mRNA production. One tain only a subset of the TAFs present in Drosophila and
key aspect of transcriptional regulation is the communi- human TFIID (Poon et al., 1995; Reese et al., 1994) and
cation between enhancer-bound gene-specific activa- that certain classes of activators are unable to function
tors and components of the basal apparatus (for review, in yeast (Attardi and Tjian, 1993; Ku¨nzler et al., 1994;
see Tjian and Maniatis, 1994). Recent studies have es- Ponticelli et al., 1995; G. Gill and R. T., unpublished data)
tablished that the transcription factor TFIID plays a criti- provided a hint that perhaps as organisms developed
cal role in receiving transcriptional activation signals more complex gene-regulatory pathways, there was a
from upstream enhancer- and promoter-binding factors concomitant increase in the need for more diversity of
and transducing them to the basal initiation complex coactivators. Indeed, several recent reports have identi-
(Horikoshi et al., 1988; Pugh and Tjian, 1990). fied mammalian cell type–specific cofactors that are
The discovery that TFIID isolated from Drosophila and required to implement activation of certain enhancer
human cells consists of TATA box–binding protein (TBP) proteins (Strubin et al., 1995; Luo and Roeder, 1995). In
and eight or more tightly associated subunits (TAFs) all cases documented thus far, these cell type–specific
provided the first clue that perhaps some TAFs could “coactivators” have been associated with activator
mediate transcriptional activation (Dynlacht et al., 1991; complexes and are not part of the TFIID complex or the
Tanese et al., 1991). Recent experiments have provided basal machinery. Thus, it became of interest to deter-
evidence that, at least in vitro, the activation domains mine whether metazoans have also evolved the use of
of different upstream regulators can recognize and bind cell type–specific TAFs.
selectively to specific TAF subunits of the TFIID complex Our previous studies have indicated that Drosophila
(Hoey et al., 1993; Goodrich et al., 1993; Chen et al., and human TFIID contain at least eight core TAFs that
are present in all cells tested (R. Weinzierl, E. Wang, N.1994; Jacq et al., 1994; Chiang and Roeder, 1995; Thut
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Figure 1. TBP–TAFs Complex in Different
Cell Types
(A) TFIID–enriched PC fractions (1 M NaCl) of
different cell types were subjected to immu-
noprecipitation using affinity-purified anti–
TBP polyclonal antibodies. The TBP–asso-
ciated polypeptides were eluted by 1.0 M
guanidine–HCl, tricholoracetic acid–precipi-
tated, resolved by 6%–15% gradient SDS–
PAGE, and stained by silver. Under these
conditions, most of TBP and the antibodies
remain bound to the protein A sepharose
beads; therefore, only traces of both can be
detected. The cell types used are indicated
on top of each lane. The position of the core
TAFs and molecular size markers are indi-
cated on the sides, and TAFII105 is indicated
by an arrow.
(B) Daudi cells 1.0 M PC fraction was used
for immunoprecipitation with two different TBP antibodies, polyclonal (lane 2) and monoclonal SL33 (lane 3), or in the absence of antibodies
(lane 1). The immune complexes were processed as in (A). The position of TAFII105 is indicated by an arrow.
(C) Immunoprecipitations of TFIID by anti–TBP antibodies from HeLa (lane 1) and Jy, EBV1 B cell line, (lane 2). The immune complexes were
processed as in (A). The asterisk indicates a polypeptide related to TAFII130, based on peptides microsequencing and cross-reactivity with
TAFII130–specific antibody. Since its appearance is not consistent (compare with Figure 1A, lane 2), we assume that it is a breakdown product.
Tanese, and R. T., unpublished data), although some specific subunit of TFIID that may function as a gene-
selective coactivator in certain cells.quantitative differences have been observed in the lev-
els of some of the smaller subunits in fractionated HeLa
TFIID complex (Jacq et al., 1994). However, to date, Results
there has been no clear evidence for cell type–specific
subunits of TFIID. A search for potential cell type– TFIID Subunits in Different Human Cell Types
To test the possibility that some TFIID subunits mightspecific TAFs is likely to be complicated by the possibil-
ity that they would be present in substoichiometric be cell type–specific, we compared the composition of
TBP–TAF complexes isolated from several human cellamounts relative to the core subunits. In addition, differ-
ences in the pattern of polypeptides associated with lines representing different tissues. For this purpose,
nuclear extracts were first fractionated by phosphocel-TFIID isolated from different cell types or tissues may
reflect alternative splicing, proteolytic processing, and lulose (PC) chromatography to separate TFIID from
other TBP–TAF complexes (i.e., SL1 and TFIIIB). Theposttranslation modifications of the ubiquitous subunits
rather than novel cell type–specific TAFs. resulting 1.0 M NaCl PC fractions were subjected to
anti–TBP affinity purification followed by SDS–poly-In an attempt to identify cell type–specific TAFs, we
have isolated TFIID from several different cell lines by acrylamide gel electrophoresis (SDS–PAGE) analysis
and staining with silver. As expected, the subunit com-antibody affinity purification, using both anti–TBP and
anti–TAF antibodies. Of the eight cell lines we tested, position and levels of the core TAFs relative to TBP were
very similar among the different cell types examinedonly highly differentiated B cells revealed the presence
of a novel large molecular mass polypeptide (105 kDa) (Figure 1A). By contrast, the TFIID complex isolated from
Daudi B cells contained an additional polypeptide ofthat selectively associated with TFIID. Consistent with
the notion of a cell type–specific TAF, this 105 kDa pro- approximately 105 kDa (Figure 1A, lane 3) that consis-
tently coimmunoprecipitated with anti–TBP antibodies.tein appears to bepresent in substoichiometric amounts
relative to the core TAFs. In order to characterize further This novel polypeptide is barely detectable in TFIID iso-
lated from non-B cells such as the neuroblastoma SK-N,this putative cell type–specific subunit, we purified the
105 kDa polypeptide from B cells to homogeneity, iso- glioblastoma U87, Jurkat and Hut78 T cells, and HeLa
cervical carcinoma.lated a cDNA clone encoding this polypeptide, and com-
pared its primary amino acid sequence with the known Association of this 105 kDa polypeptide with the TBP–
TAFs complex appears to be specific, since it can beTAFs. We also determined the levels of the 105 kDa
protein and its corresponding mRNA in the different cell coimmunoprecipitated with TFIID using a different TBP
antibody but not by mock immunoprecipitation in thetypes. Our results suggest that differentiated B cells
contain a cell type–specific subunit of TFIID, TAFII105, absence of TBP antibodies (Figure 1B). We confirmed
that the 105 kDa polypeptide is not a breakdown productthat is homologous toone of thecore subunits, providing
evidence for a family of related TAFs that includes spe- of either TAFII250 or TAFII130 by Western blot analysis,
using either anti–TAFII250 or anti–TAFII130 antibodiescialized members only found associated with TFIID in
certain cell types. Interestingly, the overexpression of (data not shown).
Daudi cells are characterized as Epstein-Barr virus–this putative cell type–specific TAF was able selectively
to “squelch” the transcription of certain B cell–specific positive (EBV1) differentiated IgG-producing B cells. To
determine whether the association of p105 with TBPgenes, but not others, in transient transfection experi-
ments. These results suggest that TAFII105 is a cell type– was either EBV– or differentiation-related, we isolated
Cell Type–Specific TAF
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Figure 2. TAFII105 Is a Substoichiometric
TFIID Subunit
(A) Immunoprecipitation of TBP–TAFs com-
plexes using either crude nuclear extracts
(lanes 1–3) or PC 1.0 M NaCl fraction (lanes
4 and 5) of Daudi and Jurkat cells. The immu-
noprecipitations were carried out by anti–
TBP antibodies or by anti–TAFII130 antibod-
ies as indicated. The immune complexes
were eluted by boiling in protein sample
buffer and resolved on 7.5% SDS–PAGE. The
positions of TBP, TAFs, and IgG are shown.
(B) Anti–TBP affinity-purified TFIID com-
plexes isolated from Daudi cells were re-
solved on SDS–PAGE and stained with silver
and Coomassie blue as indicated.
TFIID from a less differentiated EBV1 B cell, Jy, and staining methods. Antibody affinity–purified TFIID com-
plexes isolated from Daudi cells were subjected toSDS–found insignificant amounts of p105 relative to the other
TFIID subunits (Figure 1C), suggesting that EBV gene PAGE and stained by both silver and Coomassie blue
(Figure 2B). Unlike the intense bandof TAFII105 observedexpression is not likely to be responsible for the high
levels of p105 found in TFIID isolated from Daudi cells. by silver staining (left), the Coomassie-stained TAFII105
revealed that it is present in approximately 10-fold lowerTherefore, it is possible that this 105 kDa protein is a
TAF that becomes specifically associated with TFIID in levels relative to the core TAFs and TBP (right). The
apparent substoichiometric amounts of TAFII105 werehighly differentiated B cells.
further confirmed by two additional protein-staining
techniques, ponceau S and Zinc staining (data not
TAFII105 Is a Substoichiometric Subunit of TFIID shown). These results suggest that only a small fraction
To obtain independent evidence that the TAFII105 pro- (5%–10%) of the TFIID complexes within B cells contain
tein was selectively associated with TFIID rather than TAFII105.
with SL1 and TFIIIB, we used a monoclonal antibody
directed against human TAFII130 to isolate TFIID com-
plexes from either Daudi B or Jurkat T cells (Figure 2A). TAFII105 Is a Homolog of Drosophila
TAFII110 and Human TAFII130For these experiments, we used unfractionated nuclear
extracts rather than the 1.0 M NaCl PC fraction enriched In order to characterize further this candidate cell type–
specific TAF, we set out to isolate the correspondingfor TFIID, to exclude the possibility that TAFII105–
containing complexes isolated from different cell types cDNA. For this purpose, we purified TFIID from nuclear
extracts prepared from 2000 l of Daudi cells. TFIID wasmight merely reflect differential chromatographic prop-
erties. Both TBP and TAFII130 antibodies coimmuno- first fractionated over a PC column followed by anti–TBP
affinity chromatography. The TFIID polypeptides wereprecipitated TAFII105 together with the other “core”
TFIID subunits from Daudi nuclear extract (Figure 2A, resolved on a preparative SDS–PAGE gel and trans-
ferred onto nitrocellulose membrane, and the band cor-lanes 1 and 2). By contrast, only TBP and the core TAFs
were isolated by TAFII130 antibody from Jurkat nuclear responding to hTAFII105 was excised and digested with
either trypsin or Staphylococcus aureus V8 protease.extracts (Figure 2A, lane 3). To confirm these results,
we also performed immunoprecipitation using the PC The resulting peptides were separated by reversed-
phase high pressure liquid chromatography and sub-1.0 M NaCl fraction from Daudi and Jurkat cell extracts.
As expected, anti–TBP selectively precipitated the jected to microsequence analysis. The amino acid se-
quence of several peptides revealed striking similaritiesTAFII105 subunit from Daudi cells but not from Jurkat
cells (Figure 2A, lanes 4 and 5). These results strongly to the conserved C-terminal region of dTAFII110 and its
human homolog TAFII130 (N. Tanese, personal commu-suggest that TAFII105 may be a novel TAF subunit that
is only found associated with TFIID inselected cell types, nication; Figure 3). We therefore screened a Daudi cDNA
library with a DNA fragment encompassing a highly con-such as highly differentiated B cells.
We hypothesized that a TFIID complex containing a served region of hTAFII130 under low stringency hybrid-
ization conditions. A pair of cDNA clones of approxi-putative cell type–specific subunit would most likely par-
ticipate in transcription of only a limited subset of genes, mately 2 kb corresponding to TAFII105 was obtained.
These cDNAs contained a 39 poly(A) tail and a portionperhaps cell type–specific genes. Consequently, one
might expect that only a subset of TFIID complexes of the coding region of TAFII105. To isolate the remaining
portions of TAFII105, we screened several additional hu-within the cell will contain this subunit. Because silver-
staining of proteins is notoriously nonquantitative, we man cDNA libraries with TAFII105–specific probes. A pair
of additional clones was isolated, one of 1.6 kb and thehave attempted to determine the relative stoichiometry
of TAFII105 in the B cell TFIID complex by more reliable other of 3.6 kb, which overlapped the 39 region. DNA
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Figure 3. Amino Acid Sequence of TAFII105
Protein and Homology to hTAFII130 and
dTAFII110
(A) Deduced amino acid sequence derived
from the cloned 3.6 kb cDNA. Peptide se-
quences obtained from endogenous TAFII105
are underlined.
(B) Alignment of the amino acid sequence of
TAFII105 to that of the core TAFs, hTAFII130
(N. Tanese, personal communication) and
dTAFII110 (Hoey et al., 1993). The shaded
boxes represent identical residues.
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sequence analysis of the 3.6 kb insert revealed an open
reading frame of 2406 bp that included all the peptide
sequences obtained from the proteolytic digestions
(Figure 3A). When this long cDNA was expressed in Sf9
cells with a flag-tag, the size of the recombinant protein
was very similar to the endogenous TAFII105 (see Figure
6A). Since this clone does not contain a methionine
residue that is preceded by a stop codon at its most 59
region, we concluded that this cDNA encodes most but
probably not all of TAFII105. We estimate that there may
be 5–10 N-terminal residues missing from the full-length
coding sequence. Nevertheless, we were able to use
this slightly truncated cDNA to analyze further TAFII105
regulation and biochemical properties.
Amino acid sequence deduced from the DNA se-
quence of TAFII105 revealed several regions with a high
degree of similarity to hTAFII130 and dTAFII110. In partic-
ular, the C-terminal one-third of these proteins that in-
cludes domains involved in binding to other TAFs is
highly conserved (68% identity and 87% homology). In-
terestingly, additional smaller patches of identity and
some more extended regions of similarity between Figure 4. Interactions of hTAFII105 with TFIID Subunits
hTAFII105, hTAFII130, and dTAFII110 can also be found Human and Drosophila TAFs and TFIIA (large subunit) were trans-
scattered throughout the N-terminal regions (Figure 3B) lated in vitro by rabbit reticulocyte lysate in the presence of 35S-
that are thought to contain activator binding domains methionine. Labeled TAFs were used in interaction assays with im-
mobilized flag-tagged TAFII105. As a control, we incubated the la-(Hoey et al., 1993; J.-L. Chen and R. T., unpublished
beled TAFs with flag beads in the absence of TAFII105 protein. Thedata). However, the majority of the sequences in the
beads were eluted, resolved on SDS–PAGE, and autoradiographed.N-terminal region were quite diverged, suggesting that
The input represents 10% of the labeled protein used for the interac-
hTAFII105 has apparently evolved the potential to inter- tion assay. The TAFs used for the assays are indicated on top of
act with a different subset of activators than those tar- each autoradiogram.
geted by hTAFII130 and dTAFII110. The high degree of
primary protein sequence identity between hTAFII105,
hTAFII130, and TAFII110 provides additional and compel- TAFII105 can interact with each other (data not shown),ling evidence that the 105 kDa cell type–specific poly-
raising the possibility that human TFIID complexes may
peptide is indeed a bona fide TAF and that these sub-
incorporate both homo- and heterodimers of TAFII105units mayrepresent members of a family of related TAFs.
and hTAFII130.
Cell Type–Specific Association of TAFII105 withTAFII105 and dTAFII110 Share Conserved Interfaces
for Interacting with Other TFIID Subunits TFIID Is Posttranscriptionally Regulated
The finding that TAFII105 is present at high levels inExtensive analysis of the cloned TFIID subunits has indi-
cated that formation of a stable TFIID complex involves TFIID complexes isolated from B cells but not from other
cells tested suggests that its expression may also bemultiple TAF–TBP and TAF–TAF interactions (Chen et
al., 1994). To identify the subunits in TFIID that contact cell type–specific. To address potential mechanisms of
TAFII105 regulation, we determined the levels of itsTAFII105, we performed a series of protein–protein inter-
action assays using immobilized flag-tagged TAFII105 mRNA in different cell types by Northern blot analysis
with a TAFII105–specific probe. As a control, we hybrid-and 35S-labeled in vitro translated TFIID subunits (Figure
4). These experiments indicate that TAFII105 specifically ized identical samples with the ubiquitous hTAFII130
probe (Figure 5A). Our analysis of TAFII105 RNA revealedinteracts with hTAFII250 and dTAFII150, the large subunit
of TFIIA, and weakly with TBP. In contrast, TAFII105 a single transcript of about 4.6 kb that is expressed at
relatively invariant levels in all the cell types examined.did not appear to interact specifically with dTAFII60,
hTAFII70, TAFII60, dTAFII40, hTAFII32 (data not shown), To confirm this finding further, we performed RNase
protection assays. Similar amounts of RNA extracteddTAFII30a, and dTAFII30b (Figure 4). Interestingly, a simi-
lar pattern of selective protein interactions has been from different cell types were hybridized with hTAFII105–
or hTAFII250–specific probes followed by digestion withobserved for dTAFII110 (Hoey et al., 1993; Weinzierl et
al., 1993; Verrijzer et al., 1994; Yokomori et al., 1993a), RNase A and RNase T1. Here again, the levels of pro-
tected TAFII105 transcripts from different cell types ap-suggesting that these closely related TAFs have con-
served interaction surfaces (i.e., C-terminus) for incor- peared comparable. Taken together, these data suggest
that the regulation of TAFII105 may be posttranscrip-porating into the TFIID complex (J.-L. Chen, K. Yoko-
mori, F. Sauer, D. Wasserman, and R. T., unpublished tional, raising the possibility that the levels of TAFII105
protein may be regulated in a cell type–specific manner.data). An exception to this pattern of TAF–TAF interac-
tion is the ability of dTAFII110 to bind TAFII30a (Yokomori As a first step towards quantitating the amounts of
TAFII105 protein in different cells, we expressed the lesset al., 1993b). In addition, it appears that dTAFII110 and
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specific and suggest that the production of TAFII105
protein is cell type–specifically regulated.
Differential Effect of TAFII105 Overexpression
on Selected Promoters in B Cells
At present, cell type–specific activators that require
TAFII105 have not been identified. Thus, it is not practical
or possible to test directly the potential cell type–
specific coactivator properties of TAFII105. However, it
is possible to determine whether TAFII105 has any effect
on the transcription of selected genes in B cells by
relying on the phenomenon of “squelching” (Gill and
Ptashne, 1988; Berger et al., 1990; Kelleher et al., 1990).
In our case, the overexpression of a coactivator rather
than an activator should inhibit the transcription of spe-
cific genes that require the coactivator. To test whether
TAFII105 has any transcriptional function and is able to
Figure 5. Quantitative RNA Analysis of TAFII105 in Different Human squelch transcription in B cells, we determined the effect
Cell Types
of overexpressing TAFII105 on several promoters that(A) Total RNA was extracted from the indicated cell types and sub-
are expressed in B cells. Reporter gene constructsjected to Northern blot analysis using TAFII105– or TAFII130–specific
driven by the Kappa chain promoter linked either toand complementary riboprobes. The corresponding transcripts are
the intronic enhancer (kEkPLuc) or to the 39 enhancerindicated by arrows.
(B) RNase protection assays using normalized amounts of RNA (EK39kPLuc) were cotransfected along with hTAFII105
samples prepared from different human cell types that were hybrid- expression vectors into BJAB cells. In addition, we also
ized to TAFII105– or TAFII250–specific riboprobes. The protected tested a reporter containing the J chain enhancer/pro-
RNA fragments are indicated by arrows.
moter as well as a control template carrying the cyto-
megalovirus (CMV) promoter. Each of these reporter
constructs was cotransfected with increasing amounts
conserved N-terminal portion of the protein in Esche- of expression plasmids bearing TAFII105. Overexpres-
richia coli and raised polyclonal antibodies against sion of TAFII105 in BJAB cells efficiently inhibited tran-
this region of TAFII105. These anti–TAFII105 antibodies scription from both of the Kappa enhancer/promoter
specifically recognized a 105 kDa polypeptide pres- constructs (3–5-fold; Figure 7). By contrast, the expres-
ent in Daudi nuclear extract as well as recombinant sion of TAFII105 had no significant effect on J chain
TAFII105 produced in Sf9 cells (Figure 6A). As expected, promoter/enhancer transcription nor on the CMV pro-
anti–TAFII105 antibodies can also immunoprecipitate moter activity in these same cells. As might be expected
TAFII105 togetherwith all the coreTFIID subunits, includ- of a typical squelching reaction, a truncated version
ing its homolog TAFII130, from Daudi extracts (Figure of TAFII105 lacking the C-terminal TAF–TAF interaction
6B), indicating that both TAFII105 and TAFII130 might be domain but containing the putative activator interaction
present in the same complex. To measure the relative domain was also able to inhibit transcription from the
Kappa promoter/enhancer constructs (data not shown).levels of TAFII105 protein expressed in different cell
These results suggest that TAFII105 most likely functionstypes, similar amounts of nuclear extracts from different
as a coactivator or target for a subset of activatorscell types were subjected to Western blot analysis using
responsible for transcription of genes in B cells.TAFII105 and TBP antibodies. As shown in Figures 6C
and 6D, the levels of TAFII105 protein were 10–20-fold
higher in Daudi B cells than in non-B cells, suggesting Discussion
that the cell type–specific regulation of TAFII105 may
be at the level of protein expression. The anti–TAFII105 It has been well established that combinatorial arrays
antibodies were also used to compare the levels of of gene-specific DNA binding factors (i.e., activators,
TAFII105 associated with affinity-purified TFIID isolated repressors, and associated cofactors) govern the princi-
from Daudi, Jurkat, and SK-N cells (Figure 6E). These pal means by which cell type–specific gene expression
antibodies specifically detected TAFII105 in Daudi TFIID is regulated in animal cells. In this study we present
but not in Jurkat and SK-N TFIID complex. We verified evidence that the basal transcriptional apparatus may
the fact that the level of TBP in the TFIID complex was also incorporate cell type–specific components and
similar by Western blotting with TBP antibodies (data thereby provide additional mechanisms for directing tis-
not shown). Next, we looked at TAFII105 protein levels sue-specific transcription. We have identified, purified,
in another differentiated human B cell line, BJAB, and cloned, and partially characterized a novel 105 kDa hu-
in normal human tissue extracts such as B lymphocytes, man TAF that is found in TFIID isolated from differenti-
liver, colon, and brain by Western blotting (Figures 6F ated B cells but essentially undetectable in TBP–TAF
and 6G). As expected, TAFII105 was easily detected in complexes purified from a variety of other cell types
BJAB and normal B lymphocytes but not in HeLa and representing different tissues.
the other normal tissues. Taken together, these results Previous experiments indicate that transcriptional ac-
tivation by distinct classes of enhancer-binding proteinsadd support to the notion that TAFII105 is cell type–
Cell Type–Specific TAF
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Figure 6. Quantitation of TAFII105 Protein in Different Cell Types
(A) Western blot analysis of Daudi nuclear extract (lane 1) and purified recombinant flag-TAFII105 (lane 2) using anti–TAFII105 antibodies raised
against the N-terminal portion. The position of TAFII105 is indicated by an arrow.
(B) Immunoprecipitation of TFIID subunits from Daudi PC 1.0 M NaCl fraction by affinity-purified anti–TAFII105 antibodies. The immune
complexes were eluted, resolved on SDS–PAGE, and stained by silver.
(C) Western blot analysis of similar amounts of nuclear extracts prepared from different cell types using anti–TAFII105 antibodies. As a control,
we analyzed identical samples by anti–TBP antibodies.
(D) Western blot analysis of similar amounts of nuclear extracts from SK-N, Jurkat, and Daudi (lanes 5–7) and a dilution series of Daudi extract
(lanes 1–4) using anti–TAFII105 antibodies (lanes 1–7). (E) Anti–TBP affinity-purified TFIID complexes isolated from Daudi, Jurkat, and SK-N
cells were resolved on SDS–PAGE and subjected to Western blot analysis using anti–TAFII105 antibodies.
(F) Western blot analysis of nuclear extract prepared from HeLa and BJAB cells using either TAFII105 or TBP antibodies as indicated.
(G) Total cell extracts from enriched human B lymphocytes (30 mg), liver (75 mg), colon (75 mg), and brain (75 mg) were subjected to Western
blot analysis using affinity-purified TAFII105 antibodies. The position of TAFII105 is indicated by an arrow.
can be mediated by subsets of TBP–TAF complexes TAFII130/110 family of coactivators are unable to func-
tion in yeast via the glutamine-rich activation domainsand that coactivator function most likely involves direct
interactions between TAFs and activation domains of (Attardi and Tjian, 1993; Ku¨nzler et al., 1994; Ponticelli
et al., 1995; G. Gill and R. T., unpublished data). It istranscription factors (Chen et al., 1994; Jacq et al., 1994;
Chiang and Roeder, 1995; Thut et al., 1995; Sauer et al., possible that this class of TAFs that includes the cell
type–specific TAFII105 evolved to accommodate the1995). For example, glutamine-rich activation domains
of human SP1 and Drosophila bicoid were shown to more elaborated needs of transcriptional regulation in
metazoans.contact directly human TAFII130 or its Drosophila homo-
log dTAFII110 to direct transcriptional activation in vitro The primary amino acid sequence of hTAFII105 and
related members of this family of TAFs (TAFII130 and(Chen et al., 1994; Sauer et al., 1995; N. Tanese, personal
communication). Here we report that human TAFII105 is dTAFII110) reveal the presence of two distinct domains:
a highly conserved C-terminal region and an N-terminalhighly related to these two core TAFs, hTAFII130 and
dTAFII110, suggesting that these three subunits of TFIID domain containing significantly more diverged se-
quences interspersed with small patches of homology.represent different members of a family of TAFs that can
serve as transcriptional coactivators. Although many of Recent experiments with dTAFII110 mutants suggest
that the conserved C-terminal region is responsible forthe TAFs first identified in Drosophila and human TFIID
have recently also been found inyeast, thus farno homo- interacting with TAFII250 and TFIIA (F. Sauer, D. Wasser-
man, and R. T., unpublished data), whereas the lesslog of dTAFII110 or hTAFII130 has been isolated from
yeast (Poon et al., 1995; Reese et al., 1994). As one might conserved N-terminal domain of TAFII110 contains inter-
action surfaces that bind to activators (Hoey et al., 1993).expect, activators such as human SP1 and Drosophila
bicoid that use a glutamine-rich domain to target the Since many of the contacts between hTAFII105 and
Cell
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Figure 7. Overexpression of TAFII105
Squelches Transcription of Selected Genes
in B Cells
BJAB cells were transfected with 2 mg of the
indicated luciferase reporter plasmids to-
gether with increasing amounts of TAFII105
expression plasmid (0, 2, and 10 mg) and 2
mg of CMV–bgal. The normalized luciferase
activity of the reporter plasmids in the ab-
sence of TAFII105 (lanes 1, 4, 7, and 10) is
arbitrarily set as 100%.
dTAFII110 with the other TFIID subunits are conserved, nonconserved N-terminal sequences of TAFII105 have
evolved to direct interactions with certain activators thatit is likely that the homologous C-terminal domain of
TAFII105 is responsible for directing these TAF–TAF and are not targeted by human TAFII130, possibly cell type–
specific activators. However, we also expect to find acti-TAF–TBP interactions. Therefore, in differentiated B
cells one might expect to find TFIID complexes that vators that can interact with both TAFII105 and TAFII130,
since there are regions of the putative N-terminal coacti-contain either TAFII105 or TAFII130 but perhaps not both.
However, when we isolated TFIID complexes using ei- vator domain that are conserved between members of
this family of TAFs. In addition, the conserved C-terminalther anti–TAFII105 or anti–TAFII130 antibodies from B
cells, we found both polypeptides in the same complex. domain may also contain coactivator functions that
could be targeted by common activators.It is possible that in these TFIID complexes, each of the
related TAFs uses a different portion of its potential Human TFIID isolated from B cells contain substoichi-
ometric amounts of TAFII105, suggesting that only ainteraction surfaces to assemble into TFIID. An alterna-
tive explanation was provided by the finding that small proportion of the TBP–TAF complexes in these
cells contain this tissue-specific subunit. This finding isTAFII105 and TAFII110 could interact directly with each
other (R. D. and R. T., unpublished data), suggesting consistent with the notion that only a limited number of
genes, perhaps cell type–specific genes, are targetedthat TFIID from B cells may contain either homodimers
of human TAFII130 or heterodimers of human TAFII105 by TFIID complexes containing TAFII105. Consequently,
only a limited set of genes that are expressed in B cellsand 130. It is also possible that TFIID can exist as dimers
(Coleman et al., 1995; Taggart and Pugh, 1996) and that are expected to recruit TFIID complexes containing
TAFII105. It is also possible that TAFII105–containingtherefore, TFIID complexes containing both TAFII105
and TAFII130 would be coprecipitated. TFIID complexes will display other biochemical proper-
ties distinct from core TFIID, such as an altered DNABy analogy to the functional domains of dTAFII110
and hTAFII130, the N-terminal region of human TAFII105 binding specificity that is influenced by the presence of
TAFII105. Once cell type–specific enhancers and activa-is predicted to interact with activation domains. We an-
ticipate that a TFIID complex containing TAFII105 will tors that require human TAFII105 are identified, it should
be possible to address these important issues.play some role in the transcription of cell type–specific
genes, perhaps by directly contacting a subset of B cell Although we screened for putative cell type–specific
TAFs in TFIID complexes isolated from several differentenhancer–binding proteins to mediate transcription. It
will be of interest in the future to identify putative cell cell types, we have thus far failed to identify any addi-
tional cell type–specific subunits other than TAFII105.type–specific activators that will require the presence
of TAFII105 to potentiate transcriptional activation. In Our ability to detect TAFII105 initially was, in part, aided
by the fortuitous property of this protein to stain effi-this respect, it is reassuring that overexpression either
of full-length TAFII105 or of a truncated version con- ciently with silver. We do not believe that TAFII105 will
be the only substoichiometric cell type–specific subunittaining the putative activator interaction domain (N-ter-
minal region) is able to squelch differentially transcrip- associated with TFIID. Instead,we anticipate that a more
systematic screen will reveal the presence of additionaltion of selected genes in B cells. It is likely that the
Cell Type–Specific TAF
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by 50 mM glycine (pH 2.5) and 150 mM NaCl and precipitated withcell type–specific components of the TFIID complex.
trichloroacetic acid containing deoxycholate (4 mg/ml). The TAFsTo detect additional cell type–specific and potentially
were resolved by SDS–PAGE, transferred to nitrocellulose mem-developmentally regulated TAFs, it will be necessary to
brane, and stainedwith ponceau S (Sigma). The band corresponding
devise more sensitive detection methods, especially if to TAFII105 was excised and digested with either trypsin or V8 prote-
these proteins are substoichiometric and of small mo- ases, and peptides eluted from the membrane were resolved by
reversed-phase high pressure liquid chromatography and subjectedlecular mass.
to microsequencing. The amino acid sequence of the peptides ob-Interestingly, analysis of messenger RNA and protein
tained are shown in Figure 3A. Daudi cDNA library (1.5 3 106 phages)in different cell types suggests that TAFII105 may be
was screened with 237 bp probe derived from hTAFII130 (aminoposttranscriptionally regulated in a cell type–specific
acids 808–887) generated by polymerase chain reaction using the
manner. Using specific anti–TAFII105 antibodies, we oligonucleotides 59AAA/G TTT/C TTT/C GAA/G CAA/G T/C T 39 and
found significantly higher levels of TAFII105 protein in B 59CCNGGA/G CAA/G TCNACT/C TT 39. A set of two TAFII105 positive
phages was isolated, and their 1.9 and 2 kb inserts were clonedcell extracts relative to non-B cells, whereas the levels
into Bluescript KS1 (Stratagene), sequenced, and found to containof TAFII105 mRNA were comparable. Moreover, the dif-
1 kb of 39 untranslated region and 1 kb of coding region containingference in the levels of TAFII105 protein associated with
the sequence of seven peptides obtained by the proteolytic diges-TFIID in B cells versus non-B cells was even greater than
tion. To clone the N-terminus of TAFII105, we screened the following
the relative amounts of total TAFII105 protein, suggesting human cDNA libraries: human teratocarcinoma, Jurkat, HeLa, and
that both the protein levels and the association of another Daudi cDNA library. A set of two positive clones was ob-
tained from the HeLa cell library, one of 1.6 kb overlapping with theTAFII105 with TFIID may be regulated. It is possible that
clones isolated from the Daudi library and a second clone of 3.6 kbeither the protein expression or the stability of 105 in
insert. This insert was cloned in Bluescript KS1, and both strandsnon-B cells is regulated. For example, the differential
of this cDNA were completely sequenced with Bluescript orability of TAFII105 to associate with TFIID might be di- TAFII105–specific primers.
rected by cell type–specific covalent modifications. The
low levels of free TAFII105 protein in non-B cells may RNA Analysis
result in part from its inability to be stably incorporated Total cytoplasmic RNA samples were prepared from cultured cells
according to the procedure that has been described (Gough, 1988).into TFIID; thus, the free polypeptides become rapidly
For Northern blot analysis, 30 mg of RNA prepared from differentdegraded. In B cells in which TAFII105 is tightly bound
cell types was electrophoresed on a 1% formaldehyde/agarose gelto the other subunits of TFIID, proteolytic degradation
in duplicates. RNA was transferred to nitrocellulose membrane and
is likely to be mitigated. Future studies of TAFII105 in B hybridized with riboprobes complementary to either hTAFII105 or
cells and non-B cells may reveal the mechanisms that hTAFII130. For RNase protection assay, 30 mg of total RNA extracted
regulate association and assembling of cell type–speci- from different cell types were hybridizedwith anti-senseRNA probes
corresponding to hTAFII105 or hTAFII250 for 16 hr at 558C in 40 mMfic TFIID complexes.
PIPES (pH 6.7), 350 mM NaCl, 1 mM EDTA, and 80% formamide.
RNase A (40 mg/ml) and RNase T1 (2 mg/ml) were added, and diges-Experimental Procedures
tion was carried out at 308C for 30 min. The reactions were termi-
nated by the addition of 50 mg of proteinase K and 10 ml of SDSAntibodies and Immunoprecipitations
and incubation at 378C for 30 min. After phenol-chloroform extrac-Nuclear extracts from different cell types were prepared and frac-
tion and ethanol precipitation, the samples were resolved on 6%tionated by PC P11 column as described (Pugh and Tjian, 1990;
denaturing polyacrylamide gel and autoradiographed.Tanese et al., 1991). Polyclonal anti–TBP antibodies raised against
recombinant hTBP were described (Tanese et al., 1991). The anti-
Expression of TAFII105 Proteinbodies were affinity-purified using TBP–coupled affinity resins.
A 3.6 kb NotI fragment containing the entire sequences of the longMonoclonal anti–TAFII130 antibody IA5 was described (Ruppert et
cDNA was subcloned into the NotI site of the vector pVL1392. Next,al., 1993). TAFII105 polyclonal antibodieswere raised against recom-
a 3.1 kb NdeI fragment containing the coding region was subclonedbinant protein corresponding to amino acids 1–552 produced in
into the baculovirus expression vector pVLSG2Flag in NdeI site.bacteria with 6 histidine-tag. The inclusion bodies containing over-
Recombinant baculovirus was generated as described (Dikstein etexpressed TAFII105 were dissolved in 6 M urea, purified by Ni1
al., 1996). Crude extracts from cells expressing flag-TAFII105 wereagarose resin, andresolved onSDS–PAGE, andTAFII105 protein was
bound to flag antibody beads (Kodak) in 0.5 M KCl HEMG bufferexcised and injected into rabbits. Immunoprecipitations of TFIID
for 2–3 hr. After five washes with the same buffer, a small portioncomplex by affinity-purified TBP antibodies, anti–TAFII130 (IA5), and
was analyzed by SDS–PAGE. Before the interaction assays, theanti–TAFII105 were carried with TFIID–enriched PC fractions or di-
beads were washed twice with 0.1 M KCl HEMG.rectly from nuclear extracts essentially as described (Tanese et al.,
1991). Briefly, 400 mg of 1.0 M NaCl PC fraction or 5 mg of nuclear
In Vitro Binding Experimentsextracts in HEMG buffer (20 mM HEPES [ph 7.9], 100 mM KCl, 12.5
35S-labeled TAFs were synthesized in vitro by T7 RNA polymerasemM MgCl2, 0.2 mM EDTA, 0.1% NP-40, 1 mM dithiothreitol, 0.2 mM
and rabbit reticulocytes lysate and incubated with flag beads orphenylmethylsulfonyl fluoride) were incubated with antibodies and
with TAFII105 coupled to flag beads in 0.1 M KCl HEMG buffer forprotein A sepharose beads at 48C for 2–3 hr. The immune complexes
2 hr at 48C. The beads were washed five times with the same buffer,were washed with HEMG buffer five times and eluted either by 1 M
and the bound proteins were eluted by 5 min boiling in proteinguanidine–HCl followed by trichloroacetic acid precipitation or by
sample buffer followed by SDS–PAGE and autoradiography.5 min boiling in SDS–PAGE protein sample buffer.
For the Western blot analysis shown in Figure 6G, premade ex-
tracts from normal human liver, colon, and brain were purchased Plasmids and Transfection
kEkPLuc and Ek39kPLuc were generated by replacing a BamHI frag-from Clontech, and enriched B lymphocytes extract was a gift from
Dr. T. Hoey (Tularik Inc.). ment containing the CAT gene and SV40 poly A signal of kEkPCAT
(Atchison and Perry, 1987) and Ek39kPCAT (a gift from Dr. M. Atchi-
son) with a BamHI–BglII fragment containing the luciferase geneCloning of TAFII105 cDNA
Daudi cells nuclear extracts were prepared from 2000 l of culture, and SV40 pA signal from pGL2 basic vector (Promega). pGL2JEJP
was a gift from Drs. K. Chang and M. Koshland. CMV–TAFII105and TFIID–enriched fraction was obtained by PC column (Tanese
et al., 1991). TFIID was immunopurified directly from PC 1.0 M NaCl was constructed by inserting a BamHI–BglII fragment containing
TAFII105 cDNA into BamHI site of the pCMX vector. BJAB cells werefraction using cross-linked anti–TBP resin, and the TAFs were eluted
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transfected by the DEAE–Dextran method. In all the transfections, W. (1994). Functional differences between mammalian transcription
activation domains at the yeast GAL1 promoter. EMBO J. 13,the total amount of CMV promoter was adjusted to constant levels
with the pCMX plasmid. Each experiment was repeated 2–4 times 641–645.
in duplicate. Luo, Y., and Roeder, R.G. (1995). Cloning, functional characteriza-
tion, and mechanism of action of the B cell–specific transcriptional
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